Celgene

Total investments

66

Average round size

44M

Portfolio companies

46

Rounds per year

1.74

Lead investments

12

Follow on index

0.27

Exits

25

Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

In 1986 was created Celgene, which is appeared as Corporate Investor. The venture was found in North America in United States. The main office of represented Corporate Investor is situated in the Summit.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Celgene, startups are often financed by Kleiner Perkins, ARCH Venture Partners, OrbiMed. The meaningful sponsors for the fund in investment in the same round are The Column Group, OUP (Osage University Partners), Kleiner Perkins. In the next rounds fund is usually obtained by The Column Group, Kleiner Perkins, GV.

This Celgene works on 2 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 deals per year. The average startup value when the investment from Celgene is 500 millions - 1 billion dollars. The increased amount of exits for fund were in 2018. The common things for fund are deals in the range of 50 - 100 millions dollars. Speaking about the real fund results, this Corporate Investor is 5 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight NantHealth, ARMO BioSciences, Flexus Biosciences. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical Device. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low.

This organization was formed by Robert Hariri, Sol Barer. We also calculated 1 valuable employee in our database.

Show more

Investments analytics

Analytics

Total investments
66
Lead investments
12
Exits
25
Rounds per year
1.74
Follow on index
0.27
Investments by industry
  • Biotechnology (59)
  • Health Care (41)
  • Therapeutics (28)
  • Medical (25)
  • Pharmaceutical (17)
  • Show 17 more
Investments by region
  • United States (57)
  • Canada (2)
  • China (1)
  • Germany (1)
  • Switzerland (1)
  • Show 2 more
Peak activity year
2019
Number of Unicorns
4
Number of Decacorns
4
Number of Minotaurs
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
11
Avg. valuation at time of investment
137M
Group Appearance index
0.80
Avg. company exit year
6
Avg. multiplicator
1.13
Strategy success index
0.90

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
CRISPR Therapeutics 30 Apr 2015 Biotechnology, Genetics, Medical, Biopharma Early Stage Venture 29M United States, Massachusetts, Cambridge
Vividion Therapeutics 30 Apr 2019 Biotechnology, Health Care, Therapeutics Early Stage Venture 82M United States, California, San Diego
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.